Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 14%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is expected to have a strong quarter and investers are focused on the company's key growth drivers, including Padcev, Nurtec, and Vyndamax as well as upcoming data readouts in oncology and obesity. They will also be looking for updates on the company's capital allocation and business development priorities, and management's ability to navigate the upcoming patent expiration. However, Pfizer's obesity candidates may not be as strong as competitors, and more derisking is needed to gauge the company's competitive profile and manufacturing and market access capabilities.

Bears say

Pfizer is facing several risks, including potential commercial execution issues with key products, disappointing clinical data or regulatory setbacks, and a slower growth profile compared to its peers. These risks, along with Pfizer's declining EBIT margins and a relatively stable revenue outlook, contribute to a negative outlook for the stock. Additionally, while the company has made efforts to improve leadership diversity, there are still concerns about limited representation at the C-suite level. All of these factors lead to a perception that Pfizer may face challenges in maintaining its current level of success, making it a high-risk investment.

Pfizer (PFE) has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 14 analysts, Pfizer (PFE) has a Hold consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.